alue and Growth Investment Ideas Abound at THE RED CHIP REVIEW
Small-Cap Investor Conference in Minneapolis, Set for October 22
PORTLAND, Ore. and MINNEAPOLIS, Oct. 15 /PRNewswire/ -- THE RED CHIP REVIEW, the nation's leading source of independent research on small- and micro-cap stocks, will present an array of both value and growth stocks in Minneapolis on October 22, 1999. Senior management from 8 small- and micro-cap companies will present their stories at an investor conference hosted by THE RED CHIP REVIEW at the Marquette Hotel.
Marc Robins, CFA, the CEO and Editor in Chief of THE RED CHIP REVIEW will open the conference at 8:00 a.m. with remarks focusing on the state of the small-cap market. Mr. Robins, who established THE RED CHIP REVIEW six years ago after a long career as an analyst and
portfolio manager, is a nationally recognized authority on small cap stocks. He was the first analyst to recognize the potential of a then obscure small-cap company named Nike. Other stocks that Robins
spotted early in their development were Nordstrom, Alaska Air Group, Precision Castparts and Electro Scientific Industries.
''THE RED CHIP REVIEW Investor Conference is a unique opportunity for investors to gain information on quality small-cap stocks directly from company management,'' said Robins. ''Most investor conferences are targeted for retail brokers and institutional money managers. The mission of THE RED CHIP REVIEW is to make available to all investors information that is generally available only to Wall Street professionals.''
A complete list and profile of the presenting companies can be found on the RED CHIP website at www.redchip.com.
SciClone Pharmaceuticals, Inc. (Nasdaq: SCLN - news) is a rarity among biopharmaceutical companies -- it actually generates revenue from direct product sales, one of about 40 that does among the more than 400 companies in this industry. SciClone is a ''virtual business,''
licensing rather than discovering drugs, which significantly reduces its risk as well as its fixed costs. A strong cash position plus products that have demonstrated positive results in therapy for Hepatitis C and B and for Cystic Fibrosis suggest this is a stock to watch.
Investors will have an opportunity to meet the top executives of this promising group of companies, which have been screened through RED CHIP's demanding selection criteria and tough objective analyses.
Typically, companies followed by THE RED CHIP REVIEW are undervalued and underfollowed, yet they show exciting promise. Because they are smaller, they are usually nimbler in taking advantage of opportunities, and are often in the early stages of development. They tend to be fast-growing, possess a leading technology, or in some way have a unique story.
THE RED CHIP REVIEW provides in-depth research and analysis on approximately 200 publicly traded small-capitalization companies across 28 industry sectors. THE RED CHIP REVIEW is published biweekly. Visit the RED CHIP Web site at www.redchip.com.
chris |
